<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431481</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011A2116</org_study_id>
    <nct_id>NCT02431481</nct_id>
  </id_info>
  <brief_title>Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011</brief_title>
  <official_title>A Phase I, Open Label, Multicenter, Parallel-group, Single Dose Two-staged Study to Evaluate the Pharmacokinetics and Safety of a Single 400 mg Oral Dose of LEE011 in Subjects With Varying Degrees of Impaired Renal Function Compared to Matched Healthy Volunteers With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the PK and safety profile of LEE011 following a
      single oral dose in adult subjects with various degrees of renal impairment compared to a
      matched group of healthy subjects with normal renal function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2015</start_date>
  <completion_date type="Anticipated">May 4, 2018</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Pharmacokinetics (PK) parameters of LEE011 when appropriate</measure>
    <time_frame>14 days</time_frame>
    <description>Primary composite PK parameters: Cmax, AUClast, AUCinf, and CL/F. To determine the impact of various degrees of renal impairment on primary PK parameters of LEE011 following a single 400mg oral dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary PK parameters of LEE011 when appropriate</measure>
    <time_frame>14 days</time_frame>
    <description>Secondary composite PK parameters of LEE011: Tmax, T1/2, Vz/F, and CLr. To determine the impact of various degrees of renal impairment on secondary PK parameters of LEE011 following a single 400 mg oral dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of LEQ803 (i.e., Cmax, AUClast, AUCinf, Tmax, T1/2)</measure>
    <time_frame>14 days</time_frame>
    <description>Composite PK parameters of LEQ803: Cmax, AUClast, AUCinf, Tmax, T1/2. To evaluate the PK profile of LEQ803 in subjects with various degrees of renal impairment following a single 400 mg oral dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>From consent to 28 days post-dose</time_frame>
    <description>Safety profile of a single dose of LEE011 in healthy subjects and subjects with varying degrees of hepatic function includes changes observed in physical examination, changes in vital signs, changes in electrocardiograms (ECGs), abnormal laboratory results.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Normal Renal Function</condition>
  <condition>Impaired Renal Function</condition>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal renal function; matched demography to renal impariment cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe decrease in GFR (15-29 ml/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End Stage Renal Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>End stage renal disease not on dialysis; GFR &lt;15 ml/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild decrease in GFR (60-89 ml/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate decrease in GFR (30-59 ml/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>400 mg</description>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_label>End Stage Renal Disease</arm_group_label>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_label>Moderate renal impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (All Subjects):

          -  Male or female (sterile or postmenopausal) subjects between 18-75 (both inclusive)
             years of age and healthy as determined by absence of clinically significant deviation
             from normal in medical history, physical examination, vital signs, electrocardiograms,
             and clinical laboratory determinations (except for renal impaired subjects).

          -  Subjects must have a BMI between 18 kg/m2 and 38 kg/m2 and weight at least 50 kg and
             no more than 120 kg.

          -  Additional inclusion criteria for subjects with normal renal function:

               -  An absolute GFR as determined by MDRD equation and conversion within normal range
                  as determined by GFR &gt; 90 mL/min

        Inclusion Criteria (for subjects with impaired renal function):

        - Subjects must have documented stable renal disease without evidence of renal progressive
        disease (stable renal disease is defined as no significant change, such as a stable
        absolute GFR, for 4 weeks prior to study entry.

        Exclusion Criteria (All Subjects):

          -  Subject has received a renal transplant at any time in the past and is on
             immunosuppressant therapy

          -  History or presence of impaired cardiac function

          -  Any surgical or medical condition that may significantly alter the absorption,
             distribution, metabolism, or excretion of drugs

          -  Administration of CYP3A4/5 inhibitors or inducers or CYP3A4 substrates with narrow
             therapeutic windows

          -  Administration of medications that prolong the QT interval

          -  Subject has a history of immunodeficiency diseases, including HIV, as confirmed by
             (HIV-1, HIV-2) test

          -  Receipt of investigational product in another clinical trial within 4 weeks of dosing

        Exclusion Criteria (for subjects with impaired renal function):

          -  Severe albuminuria &gt; 300 mg/day

          -  Subjects undergoing any method of dialysis

          -  Subjects with renal impairment due to hepatic disease (hepatorenal syndrome)

        Other protocol-defined Inclusion/Exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-347-6206</phone>
    </contact>
    <investigator>
      <last_name>Jeffery Connaire</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <state>Czech Republic</state>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

